Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

Abstract

Three of the major biochemical pathways implicated in the pathogenesis of hyperglycemia induced vascular damage (the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)–protein kinase C (PKC) pathway) are activated by increased availability of the glycolytic metabolites glyceraldehyde-3-phosphate and fructose-6-phosphate. We have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit these three pathways, as well as hyperglycemia-associated NF-κB activation, by activating the pentose phosphate pathway enzyme transketolase, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-κB activation by activating transketolase, and also prevented experimental diabetic retinopathy. The ability of benfotiamine to inhibit three major pathways simultaneously might be clinically useful in preventing the development and progression of diabetic complications.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential mechanism by which benfotiamine blocks 4 pathways of hyperglycemic damage.
Figure 2: Effect of glucose and benfotiamine concentration on transketolase activity in cultured bovine aortic endothelial cells.
Figure 3: Effect of benfotiamine on pathways of hyperglycemic damage in cultured bovine aortic endothelial cells, in the absence and presence of transketolase inhibition by antisense oligonucleotides.
Figure 4: Effect of chronic benfotiamine administration on transketolase activity in retinas from long-term diabetic rats.
Figure 5: Effect of chronic benfotiamine administration on pathways of hyperglycemic damage in retinas from long-term diabetic rats.
Figure 6: Effect of benfotiamine on experimental diabetic retinopathy.

Similar content being viewed by others

References

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).

  2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).

  3. Wei, M., Gaskill, S.P., Haffner, S.M. & Stern, M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 7, 1167–1172 (1998).

    Google Scholar 

  4. Nishikawa, T., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790 (2000).

    Article  CAS  Google Scholar 

  5. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).

    Article  CAS  Google Scholar 

  6. Du, X.L. et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. USA 97, 12222–12226 (2000).

    Article  CAS  Google Scholar 

  7. Schenk, G., Duggleby, R.G. & Nixon P.F. Properties and functions of the thiamine diphosphate dependent enzyme transketolase. Int. J. Biochem. Cell Biol. 30, 1297–1318 (1998).

    Article  CAS  Google Scholar 

  8. Saito, N., Kimura, M., Kuchiba, A. & Itokawa, Y. Blood thiamine levels in outpatients with diabetes mellitus. J. Nutr. Sci. Vitaminol. (Tokyo) 33, 421–430 (1987).

    Article  CAS  Google Scholar 

  9. Loew, D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int. J. Clin. Pharmacol. Ther. 34, 47–50 (1996).

    CAS  PubMed  Google Scholar 

  10. Pieper, G.M. & Haq, R.U. Activation of nuclear factor B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J. Cardiovasc. Pharmacol. 30, 528–532 (1997).

    Article  CAS  Google Scholar 

  11. Lukienko, P.I., Mel'nichenko, N.G., Zverinskii, I.V. & Zabarodskaya, S.V. Antioxidant properties of thiamine. Bull. Exp. Biol. Med. 9, 303–305 (2000).

    Google Scholar 

  12. Hammes, H.P. et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA 88, 11555–11559 (1991).

    Article  CAS  Google Scholar 

  13. Ishii, H. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272, 728–731 (1996).

    Article  CAS  Google Scholar 

  14. Bitsch, R., Wolf, M., Moller, J., Heuzeroth, L. & Gruneklee, D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative. Ann. Nutr. Metab. 35, 292–296 (1991).

    Article  CAS  Google Scholar 

  15. Ascher, E. et al. Thiamine reverses hyperglycemia-induced dysfunction in cultured endothelial cells. Surgery 130, 851–858 (2001).

    Article  CAS  Google Scholar 

  16. La Selva, M. et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 39, 1263–1268 (1996).

    Article  CAS  Google Scholar 

  17. Stracke, H. et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 109, 330–336 (2001).

    Article  CAS  Google Scholar 

  18. Stevens, V.J., Vlassara, H., Abati, A. & Cerami, A. Nonenzymatic glycosylation of hemoglobin. J. Biol. Chem. 252, 2998–3002 (1977).

    CAS  PubMed  Google Scholar 

  19. Thornalley, P.J., Jahan, I. & Ng, R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J. Biochem. 129, 543–549 (2001).

    Article  CAS  Google Scholar 

  20. Kaiser, N. et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42, 80–89 (1993).

    Article  CAS  Google Scholar 

  21. Stepuro, I.I., Piletskaya, T.P., Stepuro, V.I. & Maskevich, S.A. Thiamine oxidative transformations catalyzed by copper ions and ascorbic acid. Biochemistry (Mosc.) 62, 1409–1414 (1997).

    CAS  Google Scholar 

  22. Koya, D. et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439–447 (2000).

    Article  CAS  Google Scholar 

  23. Soulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B. & Jerums, G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40, 1328–1334 (1991).

    Article  CAS  Google Scholar 

  24. Nakamura, S. et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46, 895–899 (1997).

    Article  CAS  Google Scholar 

  25. Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025–1031 (1998).

    Article  CAS  Google Scholar 

  26. Rossetti, L. & Hu, M. Skeletal muscle glycogenolysis is more sensitive to insulin than is glucose transport/phosphorylation. Relation to the insulin-mediated inhibition of hepatic glucose production. J. Clin. Invest. 92, 2963–2974 (1993).

    Article  CAS  Google Scholar 

  27. Shinohara, M. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101, 1142–1147 (1998).

    Article  CAS  Google Scholar 

  28. Kurose, I. et al. CD18/ICAM-1-dependent oxidative NF-κB activation leading to nitric oxide production in rat Kupffer cells cocultured with syngeneic hepatoma cells. J. Clin. Invest. 99, 867–878 (1997).

    Article  CAS  Google Scholar 

  29. Bierhaus, A. et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50, 2792–2808 (2001).

    Article  CAS  Google Scholar 

  30. Hammes, H.P. et al. Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids. Diabetologia 39, 251–255 (1996).

    Article  CAS  Google Scholar 

  31. Hammes, H.P., Bartmann, A., Engel, L. & Wulfroth, P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 40, 629–634 (1997).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank S. Hofmann for comments and suggestions and F. Scharpert for technical assistance. This work was supported in part by grants from the US National Institutes of Health, the Juvenile Diabetes Research Foundation, the American Diabetes Association, the Deutsche Forschungsgemeinschaft and Wörwag Pharma, GmbH & Co. KG (Böblingen, Germany).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Brownlee.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammes, HP., Du, X., Edelstein, D. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9, 294–299 (2003). https://doi.org/10.1038/nm834

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm834

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing